A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a phase 2B multicenter, randomized, double-blind, placebo-controlled, parallel group dose finding study to evaluate the safety, tolerability and efficacy of PQ912, an inhibitor of the glutaminyl cyclase enzyme, in 250 subjects with mild cognitive impairment and mild dementia due to Alzheimer \'s Disease.
Epistemonikos ID: cb0da3bfd305da390cd98bf851d2f28cb2a1295b
First added on: May 07, 2024